Oseltamivir-resistant influenza A(H1N1) pdm09 viruses, United States, 2013–14

Emerging Infectious Diseases

Volumn 21, Issue 1, 2015, Pages 136-141

  Okomo Adhiambo, Margaret ^a   Fry, Alicia M ^a   Su, Su ^a,b   Nguyen, Ha T ^a,b   Elal, Anwar Abd ^a,b   Negron, Elizabeth ^c   Hand, Julie ^d   Garten, Rebecca J ^a   Barnes, John ^a   Xiyan, Xu ^a   Villanueva, Julie M ^a   Gubareva, Larisa V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^c PENNSYLVANIA DEPARTMENT OF HEALTH   (United States)

^d Louisiana Office of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; VIRUS PROTEIN;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DISEASE SURVEILLANCE; DRUG RESISTANCE; ENZYME INHIBITION ASSAY; GENE SEQUENCE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFLUENZA VIRUS A H1N1; NONHUMAN; PHYLOGENETIC TREE; PYROSEQUENCING; SEQUENCE ANALYSIS; UNITED STATES; VIRUS ISOLATION; ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; MALE; MIDDLE AGED; PHYLOGENY; PREVALENCE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; OSELTAMIVIR; PHYLOGENY; PREVALENCE; UNITED STATES; VIRAL PROTEINS; YOUNG ADULT;

EID: 84919620855     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2101.141006     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. Seasonal influenza activity and surveillance [cited 2014 May 21]. http://www.cdc.gov/ flu/weekly/
2. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo- Adhiambo M,Pan CY, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis. 2012;18:308-11. http://dx.doi.org/10.3201/ eid1802.111466
3. Okomo-Adhiambo M, Sleeman K, Lysen C, Nguyen HT, Xu X, Li Y, et al. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir Viruses. 2013; 7:645-58. http://dx.doi.org/10.1111/irv.12113
4. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AT, et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother. 2010;54:1102-10. http://dx.doi.org/10.1128/AAC.01417-09
5. Graitcer SB, Gubareva L, Kamimoto L, Doshi S, Vandermeer M, Louie J, et al. Characteristics of patients with oseltamivirresistant pandemic (H1N1) 2009, United States. Emerg Infect Dis. 2011;17:255-7. http://dx.doi.org/10.3201/eid1702.101724
6. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284-92. http://dx.doi.org/10.1128/AAC.00555-08
7. Centers for Disease Control and Prevention. Update: influenza activity-United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:369-74.
8. Dharan NJ, Gubareva LV, Klimov AI, Fiore AE, Bresee JS, Fry AM. Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal influenza A (H1N1) infection during the 2007-2008 influenza season in the United States. Clin Infect Dis. 2010;50:621-2. http://dx.doi.org/10.1086/650178
9. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328:1272-5. http://dx.doi.org/10.1126/science.1187816
10. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis. 2012;206:148-57. http://dx.doi.org/10.1093/infdis/jis337
11. Meijer A, Jonges M, van Beek BP, Swaan CM, Osterhaus AD, Daniels RS, et al. Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill. 2012;17:20266.
12. Souza TM, Resende PC, Fintelman-Rodrigues N, Gregianini TS, Ikuta N, Fernandes SB, et al. Detection of oseltamivir-resistant pandemic influenza A(H1N1)pdm2009 in Brazil: can community transmission be ruled out? PLoS ONE. 2013;8:e80081. http://dx.doi.org/10.1371/journal.pone.0080081
13. Global Initiative on Sharing All Influenza Data [cited 2014 May 21]. www.gisaid.org
14. Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1) pdm09 influenza viruses. PLoS Pathog. 2014;10:e1004065. http://dx.doi.org/10.1371/journal.ppat.1004065
15. Sun S, Wang Q, Zhao F, Chen W, Li Z. Glycosylation site alteration in the evolution of influenza A (H1N1) viruses. PLoS ONE. 2011;6:e22844. http://dx.doi.org/10.1371/journal.pone.0022844